Mereo BioPharma Group plc Holding(s) in Company (1659S)
2020年7月6日 - 11:59PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMMPH
RNS Number : 1659S
Mereo BioPharma Group plc
06 July 2020
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible) (i)
1a. Identity of the issuer or the Mereo Biopharma Group Plc
underlying issuer of existing shares
to which voting rights are attached
(ii) :
----------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
----
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
----
An acquisition or disposal of financial instruments
----
An event changing the breakdown of voting rights
----
Other (please specify)(iii) :
----
3. Details of person subject to the notification obligation (iv)
Name (1) Citadel Advisors LLC
(2) Citadel Advisors Holdings LP
(3) Citadel GP LLC
(4) Kenneth C. Griffin
City and country of registered office (1) Delaware, USA
(if applicable) (2) Delaware, USA
(3) Delaware, USA
(4) N/A
4. Full name of shareholder(s) (if different from 3.) (v)
Name (1) Bank of America Securities
(2) Citadel Securities LLC
----------------------------------------------
City and country of registered office (1) Jacksonville, USA
(if applicable) (2) Wilmington, USA
----------------------------------------------
5. Date on which the threshold was 01/07/2020
crossed or reached (vi) :
----------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 06/07/2020
----------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer (vii)
of 8. A) (total of 8.B
1 + 8.B 2)
------------------ ---------------------- --------------- --------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 6.14169% 0.00642% 6.14812% 338,713,962
------------------ ---------------------- --------------- --------------------
Position of Below 5% Below 5% Below 5%
previous notification
(if
applicable)
------------------ ---------------------- --------------- --------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached (viii)
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares (ix)
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
--------------------------
Ordinary shares:
GB00BZ4G2K23 20,802,771 6.14169%
---------------------- -------------------------- ------------------------- ---------------------
SUBTOTAL 8. A 20,802,771 6.14169%
-------------------------------------------------- ------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument (x) (xi) be acquired if
the instrument
is
exercised/converted.
----------- ------------------------------ -------------------------------- ---------------------
SUBTOTAL 8. B 1
------------------------------ -------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date (x) Conversion cash voting rights rights
instrument Period (xi) settlement
(xii)
---------------- -------------------- -------------------- --------------------
Equity swap
referenced
to
ordinary
shares N/A N/A Cash 21,760 0.00642%
---------------- -------------------- -------------------- --------------------
SUBTOTAL 8.B.2 21,760 0.00642%
-------------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer (xiii)
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (xiv) (please add additional
rows as necessary)
Name (xv) % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
---------------------- --------------------- ------------------------
Kenneth C. Griffin 6.14169% 0.00642% 6.14812%
---------------------- --------------------- ------------------------
Citadel GP LLC 6.13315% 0.00642% 6.13957%
---------------------- --------------------- ------------------------
Citadel Advisors
Holdings LP 6.13315% 0.00642% 6.13957%
---------------------- --------------------- ------------------------
Citadel Advisors
LLC 6.13315% 0.00642% 6.13957%
---------------------- --------------------- ------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
-----------------------------------------------
The number and % of voting rights
held
-----------------------------------------------
The date until which the voting rights
will be held
-----------------------------------------------
11. Additional information (xvi)
Place of completion London
Date of completion 06 July 2020
---------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLRFMITMTAMBRM
(END) Dow Jones Newswires
July 06, 2020 10:59 ET (14:59 GMT)
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 11 2024 まで 12 2024
Mereo Biopharma (LSE:MPH)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Mereo Biopharma Group Plc (ロンドン証券取引所): 0 recent articles
その他のMereo Biopharma Group Plcニュース記事